What is the difference between mcg, mg, and IU in peptide dosing?

Micrograms (mcg or μg) and milligrams (mg) are metric mass units — 1 mg = 1,000 mcg — and most research peptides dose in the 100–1,000 mcg range rather than in milligrams. IU (International Units) measures biological activity, used for insulin and some vitamins, and doesn't apply to research peptides at all. Confusion creeps in because insulin syringes marked "units" (100 units = 1 mL) measure volume — 0.01 mL per unit — not peptide mass. Connecting syringe markings to peptide mass always requires your specific concentration calculation first.

How do I calculate the correct injection volume for my desired dose?

Two steps, always in order. First verify concentration: Concentration (mcg/mL) = Vial mass (mg) × 1,000 ÷ Reconstitution volume (mL). Then divide: Injection volume (mL) = Desired dose (mcg) ÷ Concentration (mcg/mL). Worked example: at 2,500 mcg/mL, a 250 mcg dose needs 250 ÷ 2,500 = 0.1 mL — 10 units on a U-100 syringe.

Why are peptide doses measured in micrograms rather than milligrams?

Because peptides achieve their effects at astonishingly small masses, and the reason is mechanism, not accident. Peptides bind cell-surface receptors with high affinity, and a typical receptor-binding peptide can produce a maximal biological response when fewer than 10% of available receptors are occupied — the phenomenon known as receptor reserve. Micrograms therefore suffice where small-molecule drugs need milligrams: enzyme inhibition and similar small-molecule mechanisms demand far higher molar concentrations to achieve comparable downstream signaling. The scale difference is pharmacology expressing itself through arithmetic.

Does subcutaneous injection lose some of the dose?

Yes — subcutaneous bioavailability is rarely 100%, and pretending otherwise inflates estimates. A meaningful fraction of many peptides and proteins degrades locally, binds tissue, or clears via lymph before reaching systemic circulation, with magnitude varying by injection site and formulation [PMID: 34186147]. Published SC dose ranges already reflect their route, so no correction is needed when comparing like with like. Consistency of technique, site, and depth across experimental groups matters far more than chasing a theoretical 100% absorption figure.

What is the maximum volume I can inject subcutaneously?

Parenteral tolerability literature treats volume as a major local factor, and practical guidance commonly keeps subcutaneous volumes near or below about 1–1.5 mL per site to limit pain, swelling, and absorption variability [PMID: 31587143]. Need more volume at standard concentration? Raise concentration with less solvent, split across two sites, or use an intramuscular site when the protocol allows.

How do I convert a dose from a rodent study to a human-equivalent dose?

It doesn't, and assuming it does produces bad estimates. Metabolic rate, body surface area, and clearance scale allometrically rather than linearly. The FDA recommends body surface area normalization: Human equivalent dose (mg/kg) = Animal dose (mg/kg) × (Animal Km ÷ Human Km), where Km = body weight ÷ BSA. Reference values: mouse Km = 3, rat Km = 6, human Km = 37. So 10 mcg/kg in a rat converts to roughly 10 × (6/37) ≈ 1.6 mcg/kg. Treat it as initial estimation for trial design, not direct application.

Why do some peptides require higher doses than others?

Five factors set the number: receptor affinity (how tightly the peptide binds its target), signal amplification (how much downstream response each binding event produces), distribution volume (how widely the peptide disperses through the body), metabolic clearance rate (how quickly it's degraded), and target-receptor density in the tissue of interest. High affinity plus strong amplification plus slow clearance — Semax intranasally, for instance — means micrograms suffice. Low affinity and rapid clearance demand far more mass to achieve the same biology.

What is a dose-response curve, and why does it matter?

A dose-response curve plots effect magnitude against dose, and its typical S-shape tells the whole story: nothing measurable at low doses, a steep rise through a narrow window, then a plateau where additional dose buys nothing. The curve reveals three critical values — the minimum effective dose (where effect first appears), the EC50 (the dose producing half of maximum effect, potency's standard yardstick), and the maximum effective dose beyond which escalation is wasted. Without characterizing it, a researcher cannot distinguish a genuine negative result from a dosing error: the compound tested below threshold or pushed past benefit.

Can I mix multiple peptides in the same syringe?

Technically possible, generally avoided in controlled research for three converging reasons. Peptides sharing a solution may interact chemically — cross-linking, competitive binding to excipients, pH incompatibility — altering stability or bioactivity of one or both compounds. Different degradation rates shift the ratio between them over time, quietly wrecking dose calculations mid-experiment. And if an adverse reaction occurs, attribution becomes impossible with two candidates in one barrel. Standard practice: separate injections at separate sites, independent concentration calculations, independent labeling.

Where can I find published dose ranges for specific peptides?

PubMed (https://pubmed.ncbi.nlm.nih.gov/) is the primary source — search the peptide name plus terms like 'dose-response,' 'pharmacokinetics,' 'preclinical safety,' or 'toxicology.' Animal model studies give the most specific preclinical dose data (add 'rat' or 'mouse' plus the tissue or system of interest); Phase I/II publications carry clinical dose data where it exists. ClinicalTrials.gov registers trial protocols with dose information, and FDA labeling documents cover approved peptide drugs (semaglutide, tirzepatide, liraglutide). Compound pages on CompoundGuide also reference published ranges for individual peptides.

Research Guide

Peptide Dosing Guide for Researchers

Research guide to peptide dosing: unit conversions, concentration math, SC volumes, route bioavailability, titration, and dose-response design.

Last updated Jul 15, 2026 12 min read

Somewhere between the vial label and the syringe marks, good research plans quietly go wrong. The label speaks in milligrams. The syringe speaks in units. The intended dose lives in micrograms — and a tenfold error hides inside that translation gap more often than anywhere else in peptide research. Most dosing failures are arithmetic failures, which is genuinely good news: arithmetic can be checked before anything touches a subject.

So here is this guide's promise. By the end, you'll be able to take any vial mass and any reconstitution volume and know exactly what every line on an insulin syringe delivers — no guessing, no forum folklore. Three pillars carry that skill: the unit conversions and concentration math behind every number, the dose ranges published preclinical and clinical research actually used, and the dose-response principles researchers apply when hunting a minimum effective dose.

One calibration line up front rather than repeated later: every figure here comes from published preclinical studies, clinical trials, or pharmacokinetic research. None of it constitutes dosing advice for human subjects — protocol design belongs with qualified investigators under institutional oversight.

Overview

Peptide dosing happens on a scale most pharmaceutical research never touches. A typical small-molecule drug might be dosed in hundreds of milligrams; many research peptides are biologically active at microgram levels — a thousand-fold smaller. Every step of the process inherits consequences from that gap.

The chain runs from vial to syringe. A lyophilized vial holds a known mass — typically 2 mg, 5 mg, 10 mg, or 15 mg — of dry powder. Reconstitution adds a measured volume of bacteriostatic water, creating a solution of known concentration. Drawing a calculated volume from that solution delivers the final dose.

Three variables therefore decide everything: peptide mass in the vial (set by the manufacturer), reconstitution volume (chosen by the researcher), and injection volume (calculated from desired dose and resulting concentration). Change any one and the delivered dose changes — which is why explicit, verified arithmetic isn't optional.

Bioavailability then complicates the picture, because what leaves the syringe is not what reaches circulation. Subcutaneous delivery — the workhorse route — absorbs differently by site, formulation, and molecular properties . Intramuscular behaves broadly similarly for many peptides. Oral absorption of unmodified peptides is typically very low against enzymatic and permeability barriers ; gastric-origin exceptions such as BPC-157 are studied orally in animal models but remain the exception, not the rule . Intranasal delivery bypasses first-pass metabolism for selected neuropeptides.

Concentration, finally, is not just math — it is a physical constraint. Reconstituting a 5 mg vial in 0.5 mL supports tiny injection volumes but may raise aggregation risk for some sequences. The same vial in 3 mL yields comfortable volumes approaching common subcutaneous tolerability guidance (often discussed around 1–1.5 mL per site in the parenteral literature) . Optimal concentration balances precision, comfort, and stability — the trade-off the next sections make concrete.

The Arithmetic: From Vial Label to Syringe Units

Peptide research runs on three mass units and two volume units that researchers must convert fluently — because unit-conversion errors are the single most common source of dosing mistakes in peptide protocols.

Mass units: - Milligram (mg): 1 mg = 1,000 micrograms. This is the unit used on peptide vial labels. A "5 mg vial" contains 5,000 mcg of peptide. - Microgram (mcg or μg): 1 mcg = 0.001 mg. Most research peptide doses are expressed in micrograms. A dose of 250 mcg = 0.25 mg. - Nanogram (ng): 1 ng = 0.001 mcg = 0.000001 mg. Used in pharmacokinetic measurements of plasma concentration, not in dosing.

Volume units: - Milliliter (mL): The standard volume unit. A standard insulin syringe holds 1 mL (also labeled as 100 units on U-100 insulin syringes). - Milliunit on U-100 syringes: On a U-100 insulin syringe, each "unit" mark equals 0.01 mL (10 microliters). So 10 units = 0.1 mL, 50 units = 0.5 mL, and 100 units = 1.0 mL.

The core formula for concentration:

Concentration (mcg/mL) = Peptide mass (mg) × 1,000 / Reconstitution volume (mL)

Examples: - 5 mg peptide + 2 mL BAC water = 5,000 / 2 = 2,500 mcg/mL - 10 mg peptide + 1 mL BAC water = 10,000 / 1 = 10,000 mcg/mL - 2 mg peptide + 1 mL BAC water = 2,000 / 1 = 2,000 mcg/mL

The core formula for injection volume:

Injection volume (mL) = Desired dose (mcg) / Concentration (mcg/mL)

Examples (using 2,500 mcg/mL concentration): - 250 mcg dose → 250 / 2,500 = 0.1 mL (10 units on U-100 syringe) - 500 mcg dose → 500 / 2,500 = 0.2 mL (20 units) - 125 mcg dose → 125 / 2,500 = 0.05 mL (5 units)

Common reconstitution volumes and resulting concentrations:

| Vial Mass | + 1 mL | + 2 mL | + 3 mL | |-----------|--------|--------|--------| | 2 mg | 2,000 mcg/mL | 1,000 mcg/mL | 667 mcg/mL | | 5 mg | 5,000 mcg/mL | 2,500 mcg/mL | 1,667 mcg/mL | | 10 mg | 10,000 mcg/mL | 5,000 mcg/mL | 3,333 mcg/mL |

That table is worth bookmarking, because it encodes the central trade-off. Smaller volumes mean higher concentrations — micro-dosing convenience, but elevated aggregation risk for some sequences. Larger volumes mean gentler concentrations and larger injections. For most research peptides, 1–2 mL of bacteriostatic water per 5 mg vial is the standard range — enough flexibility either direction without leaving the comfort zone.

One detail catches nearly everyone eventually: the total volume after reconstitution slightly exceeds the solvent added, because the lyophilized powder occupies real space. For precise work, measure the final volume in the vial rather than assuming it equals the solvent volume.

What Published Research Doses Actually Look Like

Published research supplies dose ranges — and the honest framing matters before any number appears. These ranges are observations from specific experimental contexts, not recommendations. Rodent doses do not transfer directly to other species; allometric differences in body surface area, metabolic rate, and renal clearance see to that.

** BPC-157 :** Preclinical studies span an unusually wide range. A formal safety evaluation and multiple experimental models report doses from microgram-to-milligram per kilogram levels, delivered intraperitoneally, subcutaneously, or orally . Mechanistic and tendon-healing work commonly uses low mcg/kg regimens, documenting cell-migration and growth-hormone receptor effects at research doses . Narrative reviews summarize the still-preclinical evidence base and its delivery challenges .

Oral administration deserves its own sentence: if oral bioactivity confirms across endpoints, it would matter enormously, since most peptides are destroyed in the GI tract . Leading hypotheses invoke gastric origin and relative acid/pepsin resistance, but formulation and translation remain open problems .

** TB-500 ( Thymosin Beta-4 fragment):** Commercial "TB-500" products are typically actin-binding-domain fragments of thymosin β4 (Tβ4), not full-length Tβ4 — a distinction that changes everything about dose interpretation. Preclinical and translational literature on full-length Tβ4 describes multi-functional tissue-repair activity across dermal, angiogenic, and regenerative models . Rodent wound studies using Tβ4 peptides report mcg-range topical or systemic dosing depending on model . Human clinical experience involves full-length Tβ4 regimens rather than commercial fragment products — treat fragment dosing as non-equivalent unless a study specifies the exact sequence.

** GHK-Cu :** Dose depends entirely on route. Topical and formulation work uses low-percentage leave-on or wound-care concentrations, with reviews describing multi-pathway skin-regeneration effects . Reported subcutaneous animal regimens are model-specific and shouldn't cross species lines without allometric justification.

Bioavailability by route (typical order-of-magnitude framing for unmodified peptides):

| Route | Typical Bioavailability | Notes | |-------|------------------------|-------| | Subcutaneous (SC) | Variable; often substantial for many peptides | Injection site and formulation matter | | Intramuscular (IM) | Variable; often similar order to SC | Used for some formulations | | Intraperitoneal (IP) | High in rodents | Common in animal studies; not a human clinical route | | Intravenous (IV) | 100% (by definition) | Bypasses absorption; most precise but invasive | | Intranasal | Moderate for selected peptides | Bypasses first-pass; used for neuropeptides | | Oral | Typically very low for unmodified peptides | GI degradation and permeability barriers | | Topical | Highly variable | Depends on size, vehicle, and skin barrier |

Volume imposes its own ceiling on subcutaneous work. Parenteral literature treats injection-site pain and tolerability as volume-dependent, with practical guidance commonly keeping SC volumes near or below about 1–1.5 mL per site for comfort and predictable absorption . Beyond that range, pain, swelling, and absorption variability climb — so when a dose needs more volume than that at standard concentration, researchers raise concentration instead or split across two sites.

And when translating rodent doses toward other species, remember the scaling trap: body surface area normalization (mg/m²), not simple mg/kg, is the standard approach. A 10 mcg/kg dose in a 25 g mouse is not 10 mcg/kg anywhere else. FDA allometric guidance provides conversion factors, though they were built for conventional drugs and may miss peptide-specific pharmacokinetics.

Dose–Response Design and Titration Principles

Give twice the dose, get twice the effect? Almost never. For most pharmacologically active compounds the relationship traces a sigmoidal curve: nothing measurable below a threshold, steep escalation through a narrow band, then a plateau where more dose buys nothing.

Characterizing that curve is a primary objective of early-stage research, and its vocabulary is worth owning:

- Minimum effective dose (MED): The lowest dose at which a statistically significant effect is observed relative to control. - EC50 / ED50: The dose producing 50% of the maximum effect. This is the standard measure of a compound's potency. - Maximum effective dose: The dose above which no further increase in effect occurs. - Therapeutic index (in clinical contexts): The ratio between the toxic dose and the effective dose. For research peptides in preclinical stages, this is estimated from toxicology studies.

Standard design follows accordingly: 3–5 dose groups plus a vehicle control, 6–12 subjects per group depending on expected variability, doses spaced at half-log intervals (1, 3, 10, 30, 100 mcg/kg) to capture the curve's shape without bloating group counts.

Titration applies the same logic over time. Progressive dose increases from a low starting point serve three purposes:

1. Safety: Starting low and increasing gradually minimizes the risk of adverse reactions at supratherapeutic doses. 2. Individual variability: Biological systems vary. A dose that is subthreshold for one subject may be supratherapeutic for another. Titration allows each subject to find their individual response level. 3. Receptor dynamics: Many peptide receptors undergo desensitization (downregulation) when exposed to sustained high concentrations. Beginning with lower doses preserves receptor sensitivity.

The GLP-1 receptor agonists supply the best-documented titration model available. In STEP 1, weekly semaglutide escalated from 0.25 mg through 0.5 mg and 1.0 mg to a 2.4 mg maintenance dose, with stepwise increases designed to improve gastrointestinal tolerability . Semaglutide pharmacokinetics — albumin binding, multi-day half-life — support that weekly rhythm . SURPASS-2 ran comparable weekly escalations for dual agonist tirzepatide . These clinical ladders illustrate balancing effect against gastrointestinal cost — they are models of a principle, not templates for unapproved research peptides.

Where no clinical titration protocol exists, the principle still transfers: begin at the lowest literature-reported dose, escalate incrementally across cohorts, track primary endpoints and safety biomarkers at each step.

Frequency and duration close the design loop. Half-life dictates frequency — short-half-life compounds may need daily or twice-daily dosing to hold target concentrations, while engineered long-exposure analogues stretch to weekly. Semaglutide 's fatty-acid albumin-binding strategy extends exposure from native GLP-1's minutes-scale half-life to roughly one week . Duration then follows the question: acute single-dose pharmacokinetics versus chronic 2–12 week efficacy studies measuring tissue-level change.

Putting Dosing Principles Together

Three Skills, One Protocol

Concentration math, bioavailability knowledge, and dose-response design fail separately and succeed together. A researcher who calculates concentrations flawlessly but ignores bioavailability delivers an effective dose by one route and a subtherapeutic one by another at the same injection volume. A researcher who designs an elegant dose-response study on sloppy concentration math places subjects in entirely wrong dose groups.

Working as a system: the arithmetic guarantees the right mass reaches the syringe. Bioavailability translates administered dose into realistic expectations of circulating compound. Dose-response design structures the experiment so the dose-effect relationship emerges with statistical rigor.

In practice, a complete protocol states explicitly: the peptide mass in the vial, the reconstitution volume and resulting concentration, the injection volume at each dose level, the route of administration with estimated bioavailability, and the dose expressed in both mcg and mcg/kg for weight-normalized designs.

Multi-peptide studies multiply the discipline. BPC-157 alongside TB-500 in a repair study means independent concentration calculations and potentially different reconstitution volumes per compound — reconstituting every vial identically optimizes convenience, not science.

And the literature remains the starting point, never the destination: species, strain, age, sex, health status, and endpoint each demand calibration within the researcher's own system. Published ranges are guidelines; your experiment writes the prescription.

Frequently Asked Questions

: Micrograms (mcg or μg) and milligrams (mg) are metric mass units — 1 mg = 1,000 mcg — and most research peptides dose in the 100–1,000 mcg range rather than in milligrams. IU (International Units) measures biological activity, used for insulin and some vitamins, and doesn't apply to research peptides at all. Confusion creeps in because insulin syringes marked "units" (100 units = 1 mL) measure volume — 0.01 mL per unit — not peptide mass. Connecting syringe markings to peptide mass always requires your specific concentration calculation first.
: Two steps, always in order. First verify concentration: Concentration (mcg/mL) = Vial mass (mg) × 1,000 ÷ Reconstitution volume (mL). Then divide: Injection volume (mL) = Desired dose (mcg) ÷ Concentration (mcg/mL). Worked example: at 2,500 mcg/mL, a 250 mcg dose needs 250 ÷ 2,500 = 0.1 mL — 10 units on a U-100 syringe.
: Because peptides achieve their effects at astonishingly small masses, and the reason is mechanism, not accident. Peptides bind cell-surface receptors with high affinity, and a typical receptor-binding peptide can produce a maximal biological response when fewer than 10% of available receptors are occupied — the phenomenon known as receptor reserve. Micrograms therefore suffice where small-molecule drugs need milligrams: enzyme inhibition and similar small-molecule mechanisms demand far higher molar concentrations to achieve comparable downstream signaling. The scale difference is pharmacology expressing itself through arithmetic.
: Yes — subcutaneous bioavailability is rarely 100%, and pretending otherwise inflates estimates. A meaningful fraction of many peptides and proteins degrades locally, binds tissue, or clears via lymph before reaching systemic circulation, with magnitude varying by injection site and formulation [PMID: 34186147]. Published SC dose ranges already reflect their route, so no correction is needed when comparing like with like. Consistency of technique, site, and depth across experimental groups matters far more than chasing a theoretical 100% absorption figure.
: Parenteral tolerability literature treats volume as a major local factor, and practical guidance commonly keeps subcutaneous volumes near or below about 1–1.5 mL per site to limit pain, swelling, and absorption variability [PMID: 31587143]. Need more volume at standard concentration? Raise concentration with less solvent, split across two sites, or use an intramuscular site when the protocol allows.
: It doesn't, and assuming it does produces bad estimates. Metabolic rate, body surface area, and clearance scale allometrically rather than linearly. The FDA recommends body surface area normalization: Human equivalent dose (mg/kg) = Animal dose (mg/kg) × (Animal Km ÷ Human Km), where Km = body weight ÷ BSA. Reference values: mouse Km = 3, rat Km = 6, human Km = 37. So 10 mcg/kg in a rat converts to roughly 10 × (6/37) ≈ 1.6 mcg/kg. Treat it as initial estimation for trial design, not direct application.
: Five factors set the number: receptor affinity (how tightly the peptide binds its target), signal amplification (how much downstream response each binding event produces), distribution volume (how widely the peptide disperses through the body), metabolic clearance rate (how quickly it's degraded), and target-receptor density in the tissue of interest. High affinity plus strong amplification plus slow clearance — Semax intranasally, for instance — means micrograms suffice. Low affinity and rapid clearance demand far more mass to achieve the same biology.
: A dose-response curve plots effect magnitude against dose, and its typical S-shape tells the whole story: nothing measurable at low doses, a steep rise through a narrow window, then a plateau where additional dose buys nothing. The curve reveals three critical values — the minimum effective dose (where effect first appears), the EC50 (the dose producing half of maximum effect, potency's standard yardstick), and the maximum effective dose beyond which escalation is wasted. Without characterizing it, a researcher cannot distinguish a genuine negative result from a dosing error: the compound tested below threshold or pushed past benefit.
: Technically possible, generally avoided in controlled research for three converging reasons. Peptides sharing a solution may interact chemically — cross-linking, competitive binding to excipients, pH incompatibility — altering stability or bioactivity of one or both compounds. Different degradation rates shift the ratio between them over time, quietly wrecking dose calculations mid-experiment. And if an adverse reaction occurs, attribution becomes impossible with two candidates in one barrel. Standard practice: separate injections at separate sites, independent concentration calculations, independent labeling.
: PubMed (https://pubmed.ncbi.nlm.nih.gov/) is the primary source — search the peptide name plus terms like 'dose-response,' 'pharmacokinetics,' 'preclinical safety,' or 'toxicology.' Animal model studies give the most specific preclinical dose data (add 'rat' or 'mouse' plus the tissue or system of interest); Phase I/II publications carry clinical dose data where it exists. ClinicalTrials.gov registers trial protocols with dose information, and FDA labeling documents cover approved peptide drugs (semaglutide, tirzepatide, liraglutide). Compound pages on CompoundGuide also reference published ranges for individual peptides.

Summary

Dosing is where peptide research pays for its precision or forfeits it. At microgram scales, small errors in conversion, concentration, or volume become proportionally enormous errors in delivered dose — so mastering the chain from mass to concentration to volume precedes everything else in the protocol.

Bioavailability adds the second layer: the same mass by different routes produces different systemic exposures. Subcutaneous injection delivers roughly half to most of a dose to circulation depending on compound, site, and technique; oral delivery, for most peptides, delivers very little. Interpreting published ranges without that context misreads them — a dose that looks identical on paper may differ severalfold in circulation.

Dose-response design completes the toolkit: start low, escalate deliberately, characterize the full curve, and titration becomes principled rather than guesswork.

For primary literature, PubMed remains the authoritative source of dosing information through pharmacokinetic studies, toxicology reports, and dose-ranging experiments. Reconstitution specifics live in the Peptide Reconstitution Guide; storage and stability in Peptide Storage & Handling.

I. Overview

II. The Arithmetic: From Vial Label to Syringe Units

III. What Published Research Doses Actually Look Like

IV. Dose–Response Design and Titration Principles

V. Putting Dosing Principles Together

VI. Frequently Asked Questions

Frequently Asked Questions

VII. Summary

Overview

The Arithmetic: From Vial Label to Syringe Units

What Published Research Doses Actually Look Like

Dose–Response Design and Titration Principles

Putting Dosing Principles Together

Frequently Asked Questions

Summary